دورية أكاديمية

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.

التفاصيل البيبلوغرافية
العنوان: Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
المؤلفون: Takeuchi, Ario, Shiota, Masaki, Tatsugami, Katsunori, Yokomizo, Akira, Eto, Masatoshi, Inokuchi, Junichi, Kuroiwa, Kentaro, Kiyoshima, Keijiro, Naito, Seiji
المصدر: Cancer Chemotherapy & Pharmacology; Dec2011, Vol. 68 Issue 6, p1557-1564, 8p
مصطلحات موضوعية: ANTINEOPLASTIC agents, CANCER treatment, RENAL cell carcinoma, PROTEIN-tyrosine kinases, CYTOKINES, GENE expression, TUMOR growth, DRUG side effects
مستخلص: Purpose: Sorafenib, a multikinase and tyrosine-kinase inhibitor, has anti-tumor activity in patients with advanced renal cell carcinoma (RCC). Recently, we reported that S-1 was active and well tolerated for the treatment of cytokine-refractory metastatic RCC. Therefore, we hypothesized that S-1 might be a good candidate for combination therapy with molecular targeting agents. In this study, we examined the mechanisms underlying for the synergism between S-1 and Sorafenib for RCC treatment in vitro and in tumor-bearing murine models. Methods: Human RCC cell lines were used for the in vitro cell proliferation assay. ACHN and 786-O tumors were subcutaneously transplanted into NCr-nu/nu-mice. Mice were treated with S-1 and/or Sorafenib, and tumor growth and side effects were monitored. Results: Synergistic anti-proliferative effects of Sorafenib and S-1 were clearly demonstrated in ACHN and 786-O cell lines in vitro due to the suppression of TS and E2F-1 expression. In the NCr-nu/nu model, the synergistic anti-tumor effects of S-1 and Sorafenib were again clearly seen, indicating direct synergistic effects of each drug on tumor growth. Conclusions: Our results demonstrate the synergistic activity of S-1 and Sorafenib and provided the rationale for combination therapy with S-1 and Sorafenib for the treatment of patients with advanced RCC. [ABSTRACT FROM AUTHOR]
Copyright of Cancer Chemotherapy & Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:03445704
DOI:10.1007/s00280-011-1660-6